touchEXPERT OPINIONS What’s new for eosinophilic oesophagitis? A case-based discussion of patient care
Watch experts give their perspective on different aspects of managing patients with EoE, based on clinical case studies.
Exploring the pathophysiology and clinical manifestations of EoE
Dr Stuart Carr provides his perspective on the latest understanding of the aetiology, pathophysiology and clinical manifestations of EoE.
1/3 Next InterviewIn this interview, Dr Carr answers the following questions:
- What is the latest understanding of the different environmental and genetic factors associated with EoE development?
- What is the role of T helper type 2 cells in EoE and is EoE associated with any other type-2 inflammatory diseases?
- What is the latest understanding regarding the role of milk and IgG4 in EoE?
- How does the pathophysiology of EoE manifest clinically in terms of what is seen during endoscopy or in biopsy samples?
Stuart Carr, MD FRCPC FAAAAI, is chief medical officer at Snö Asthma & Allergy Clinic in Abu Dhabi, UAE. read more
Previously, Dr Carr was associate clinical professor at the University of Alberta, and he was past-president of the Canadian Society of Allergy and Clinical Immunology (CSACI). He currently serves as a reviewer for Allergy, Asthma & Clinical Immunology, the journal of the CSACI.
Dr Carr’s primary interests are paediatric asthma, food allergy and eosinophilic oesophagitis. Dr Carr is currently involved in a Canadian-wide collaboration examining the safety and effectiveness of oral immunotherapy for peanut and other food allergies in preschool children.
Dr Stuart Carr discloses Advisory board/panel fees from Sanofi/Genzyme. Consultancy fees from Aralez Canada. Speaker’s bureau fees from Sanofi/Genzyme.
Managing EoE: Diagnosis and treatment of paediatric patients
Dr Mário Vieira provides his perspective on the diagnosis and management of paediatric patients with EoE, based on an example patient case.
2/3 Next InterviewIn this interview, Dr Vieira answers the following questions:
- Please could you introduce the patient case?
- Are this patient’s symptoms typical of how EoE presents in children of any age?
- What are the current choices for first and subsequent lines of treatment for children with EoE?
- What is the potential for biological therapies in children based on the current and emerging data?
- How can we monitor disease activity and treatment response in patients with EoE?
- Thinking back to our patient case, how would you treat and monitor disease activity for this child?
Dr Mário C Vieira, MD MSc PhD, is head of the Division of Pediatric Gastroenterology and Gastrointestinal Endoscopy at Hospital Pequeno Príncipe, Curitiba, Brazil. read more
Dr Vieira trained in Brazil and at St. Bartholomew’s Hospital, London, UK, and set up a paediatric gastroenterology unit at Hospital Pequeno Príncipe (a 380-bed paediatric teaching hospital), Curitiba, Brazil, in 1994.
Dr Vieira runs a busy practice-based referral unit involving different aspects of paediatric gastroenterology and gastrointestinal endoscopy.
Dr Mário Vieira discloses Advisory board/panel fees from Danone Nutricia. Speaker’s bureau fees from Aché Laboratories, Danone Nutricia and Nestlé Nutrition.
Managing EoE: Diagnosis and treatment of adult patients
Prof. Arjan Bredenoord provides his perspective on the diagnosis and management of adult patients with EoE, based on an example patient case.
3/3 Take CE/CME TestIn this interview, Prof. Bredenoord answers the following questions:
- Please could you introduce the patient case?
- Which differential diagnoses might you consider for this patient and how might you confirm the diagnosis?
- What are the current treatment options for this patient and how effective are they?
- What are the emerging biologic treatment options for patients with EoE and what do the data tell us?
- How can we monitor treatment outcomes and disease progression in this patient and generally in adult patients with EoE?
Arjan Bredenoord, MD, is consultant gastroenterologist at the Amsterdam University Medical Center (AMC), and professor of neurogastroenterology and motility at the University of Amsterdam in the Netherlands. read more
In his current work as a consultant gastroenterologist, Prof. Bredenoord is dedicated to patient care, scientific research and education in the field of benign oesophageal diseases. Prof. Bredenoord’s main focus is on achalasia, reflux disease and eosinophilic oesophagitis. He is one of the pioneers of high-resolution manometry and impedance monitoring of the oesophagus. The oesophageal clinic at the AMC hosts the largest population of benign oesophageal diseases in the Netherlands.
Prof. Bredenoord is an author of over 250 articles, books and book chapters. He organizes regular courses in Europe, North America and Asia. He is past president of the European Society of Eosinophilic Esophagitis (EUREOS), member of the United European Gastroenterology (UEG) Scientific Committee, and co-founder of the International High-Resolution Manometry (HRM) working group.
Prof. Arjan Bredenoord discloses Advisory board/panel fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Consultancy fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Grants/research support from Nutricia and Thelial; Bayer, Dr. Falk Pharma, Gossamer Bio, Norgine and SST (relationships terminated). Speaker’s bureau fees from AstraZeneca, Dr. Falk Pharma, Laborie, Medtronic, Regeneron Pharmaceuticals Inc. and Sanofi.
Overview & Learning Objectives
Overview
In this activity, international experts discuss the latest understanding of eosinophilic oesophagitis (EoE) pathophysiology, how to differentiate EoE from gastro-oesophageal reflux disease, and current and future treatment and monitoring options for patients with EoE.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of adult and paediatric gastroenterologists, adult and paediatric allergists/immunologists, paediatricians, advanced nurse practitioners, physician assistants and practice nurses involved in the management of patients with eosinophilic oesophagitis.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Stuart Carr discloses: Advisory board/panel fees from Sanofi/Genzyme. Consultancy fees from Aralez Canada. Speaker’s bureau fees from Sanofi/Genzyme.
Dr Mário Vieira discloses: Advisory board/panel fees from Danone Nutricia. Speaker’s bureau fees from Aché Laboratories, Danone Nutricia, Nestlé Nutrition.
Prof. Arjan Bredenoord discloses: Advisory board/panel fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Consultancy fees from Alimentiv, Arena Pharmaceuticals Inc., AstraZeneca, Calypso Biotech, Dr. Falk Pharma, EsoCap, Laborie, Medtronic, Reckitt, Regeneron Pharmaceuticals Inc. and Sanofi. Grants/research support from Nutricia and Thelial; Bayer, Dr. Falk Pharma, Gossamer Bio, Norgine and SST (relationships terminated). Speaker’s bureau fees from AstraZeneca, Dr. Falk Pharma, Laborie, Medtronic, Regeneron Pharmaceuticals Inc. and Sanofi.
Content reviewer
John Jacobs MD has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Directors
Anne Nunn and Kathy Day have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 18 August 2022. Date credits expire: 18 August 2023.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the complex pathophysiology of EoE and how this manifests as clinical symptoms throughout life
- Distinguish eosinophilic oesophagitis as a progressive disease that is distinct from GORD
- Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE
Register to touchIMMUNOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
